Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats

Table 2

In vivo pharmacokinetics parameters of insulin glargine with or without SBE7-β-CyD (200 mM). (1) Time required to reach the maximum serum insulin glargine level. (2) Maximum serum insulin glargine level. (3) Area under the serum insulin glargine level-time curve up to 12 h after-administration. (4) Mean residence time in plasma. Each value represents the mean ± S.E.M. of 4–6 experiments. *𝑃<0.05, compared to insulin glargine.

System	Tmax^(1) (h)	Cmax^(2) (𝜇U/mL)	AUC^(3) ((mU/mL)h)	MRT^(4) (h)
Insulin glargine	1.00±0.00	150.00±17.90	582.99±30.27	1.83±0.08
Insulin glargine/SBE7-𝛽-CyD	1.40±0.24	91.60±3.04^∗	687.86±20.57^∗	2.12±0.04^∗